10-Q · May 14, 2026
MediciNova, Inc. reported revenues of $0.2 million for Q1 2026, a notable increase from $0.0 million in Q1 2025. Operating losses persist due to high research and administrative expenses, with a reported EPS of -0.06,…
Earnings analysis · 10-Q
MNOV earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
MediciNova delivered strong year-over-year revenue growth to $458,439 in the second quarter, alongside a narrower net loss of $2,314,139 and improved diluted loss per share of $0.05. Lower R&D spending helped reduce the…
Read full summary
MediciNova delivered strong year-over-year revenue growth to $458,439 in the second quarter, alongside a narrower net loss of $2,314,139 and improved diluted loss per share of $0.05. Lower R&D spending helped reduce the loss, but the company remains materially unprofitable, with six-month operating cash burn of $5,390,262 and cash declining to $25.4 million. Management believes liquidity can fund operations through at least November 2027, but expects continued losses and additional capital requirements. No material changes to previously disclosed risk factors were reported and no numeric guidance was provided.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.05
- Segment
- Single operating segment: acquisition and development of small molecule therapeutics; revenue was $458,439 for the three months ended June 30, 2026 and $645,423 for the six months ended June 30, 2026.
What stood out
-
Revenue increased sharply year over year
Revenue increased to $458,439 from $134,599 in the year-ago quarter, a $323,840 or 240% increase. Management attributed the increase primarily to changes in estimates regarding progress on the Mayo clinical research services agreement.
-
Quarterly loss and EPS improved
Net loss narrowed to $2,314,139 from $3,281,185 in the prior-year quarter, while diluted loss per share improved to $0.05 from $0.07.
-
Operating expense base declined
Total operating expenses declined to $2,999,628 from $3,741,691 year over year, primarily reflecting a $1.2 million reduction in R&D and patent expenses.
-
Lower clinical development spending
R&D and patent expense fell to $1.0 million from $2.2 million, driven by a $1.0 million decrease in MN-166 expenses and a $0.1 million decrease in MN-001 clinical-trial expenses.
-
Operating cash burn moderated
Net cash used in operating activities improved to $5,390,262 for the six months ended June 30, 2026, versus $6,090,067 in the comparable 2025 period, a $699,805 improvement.
-
Liquidity runway extended
Management reported $25.4 million of cash and cash equivalents and $23.0 million of working capital at June 30, 2026, and stated that working capital was sufficient to fund operations at least through November 2027.
What to watch
-
Persistent losses and accumulated deficit
The company had an accumulated deficit of $443.6 million at June 30, 2026 and reported a net loss of $4,900,397 for the six months ended June 30, 2026. Management expects substantial net losses for the next several years.
-
Continued cash burn reduces liquidity
Six-month operating cash flow remained negative at $5,390,262, while cash and cash equivalents declined to $25,415,921 from $30,806,477 at December 31, 2025.
-
Future financing remains necessary
Management stated that the company will require additional capital to advance its clinical programs and cannot be certain that funding will be available on acceptable terms, or at all. No shares were sold under either the SEPA or equity distribution agreement during the six months ended June 30, 2026.
-
Potential milestone obligations
Future potential milestone payments for MN-166 and MN-001 totaled $10.0 million, with an additional $16.5 million related to other products; the timing of these payments cannot be estimated with certainty.
-
Revenue concentration and contract timing
Revenue was concentrated in the Mayo agreement: $458,439 of quarterly revenue and $645,423 of six-month revenue came from clinical research services. The initial term of the agreement was extended only until August 2026.
-
R&D and administrative spending pressure
Management said R&D costs are expected to remain at current levels through the remainder of 2026, while quarterly general and administrative expense increased to $1,829,784 from $1,436,690 due primarily to higher professional fees.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management stated that R&D costs are expected to be maintained through the remainder of 2026 and that the company expects to continue incurring losses and require additional capital.
Earlier filings 4
10-K · March 10, 2026
MediciNova's 2025 10-K emphasizes a development-stage biotech strategy focused on advancing MN-166 (ibudilast) across multiple neurological indications and MN-001 (tipelukast) for fibrotic/metabolic diseases, relying on…
10-Q · November 12, 2025
MediciNova reported Q3 2025 revenue of $123,319 and a net loss of $3,050,373 (loss per share $0.06). Operating expenses rose modestly to $3,504,317 and cash and cash equivalents declined to $32.6M, though management…
10-Q · May 13, 2025
MediciNova reported a largely stable quarter with a net loss of $2,864,120 (basic and diluted loss per share of $0.06) and operating expenses of $3,202,510 for the three months ended March 31, 2025. Cash and cash…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.